Stratos Wealth Partners’s Recursion Pharmaceuticals RXRX Stock Holding History

Stratos Wealth Partners’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$307K	Sell	99,894 -16,540	-14%	-$63.9K	﹤0.01%	1306
2025 Q4	$476K	Buy	116,434 +5,823	+5%	+$28.8K	0.01%	1066
2025 Q3	$540K	Buy	110,611 +11,907	+12%	+$62.5K	0.01%	983
2025 Q2	$499K	Buy	98,704 +86,730	+724%	+$426K	0.01%	927
2025 Q1	$63.3K	Sell	11,974 -4,579	-28%	-$33.4K	﹤0.01%	1333
2024 Q4	$112K	Buy	+16,553	New	+$111K	﹤0.01%	1395
2024 Q2	–	Sell	-13,436	Closed	-$134K	–	1437
2024 Q1	$134K	Buy	+13,436	New	+$150K	﹤0.01%	1324

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Stratos Wealth Partners's RXRX Position: Q1 2026 in Review

Stratos Wealth Partners reduced its Recursion Pharmaceuticals (RXRX) stake by 14% in Q1 2026, selling an estimated $63.9K and leaving 99,894 shares worth $307K. The position accounts for ﹤0.01% of the portfolio, ranked #1306.

Stratos Wealth Partners first reported a position in RXRX in Q1 2024 and has held it in 7 quarters since. The position peaked at $540K in Q3 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

Stratos Wealth Partners held 99,894 shares of Recursion Pharmaceuticals worth $307K as of Q1 2026.
Stratos Wealth Partners sold 16,540 Recursion Pharmaceuticals shares in Q1 2026, an estimated $63.9K.
Recursion Pharmaceuticals made up ﹤0.01% of Stratos Wealth Partners's portfolio in Q1 2026, its #1306 holding.
Stratos Wealth Partners first reported a position in Recursion Pharmaceuticals in Q1 2024 and has held it in 7 quarters since.
Stratos Wealth Partners's Recursion Pharmaceuticals position peaked at $540K in Q3 2025.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Stratos Wealth Partners's 13F filing for Q1 2026, filed 28 Apr 2026.